An Update On Rodent Model Studies In Diabetic Neuropathy: A Brief Communication by Rolim Lima, Nadia Nara et al.
InternatIonal archIves of MedIcIne 
sectIon: neurology
ISSN: 1755-7682
International 
Medical Society 
http://imedicalsociety.org
1
2016
Vol. 9 No. 380
doi: 10.3823/2251
© Under License of Creative Commons Attribution 3.0 License This article is available at: www.intarchmed.com and www.medbrary.com 
Abstract
The diseases of the peripheral nerves are quite common and diver-
sified, are directly related to several factors, ranging from the im-
balance related to good nutrition and adequate needs of nutrients, 
going to the injuries caused by drugs or mechanisms external to 
the human organism. Diabetes is a complex syndrome that affects 
and kills millions of people worldwide. We demonstrated through 
the experimental model of diabetes using STZ@ in single intraperi-
toneal dose of 60 mg / kg, that both a purely motor nerve can be 
directly affected as well as a special afferent nerve (cranial nerve), 
this comparison showed us that there is a possibility of having a new 
type of mixed type neuropathy, this may be related to the amount 
of the dose involved, such as the time of disease progression, but 
more studies need to be done for definitive confirmation. We can 
extrapolate the original results to understand the mechanisms of 
diabetes in humans, although it does not yet have an experimental 
model of type II diabetes, more related to eating disorders, the STZ 
application simulates the effects of type I or insulin dependent dia-
betes, with more serious and deleterious effects mainly the more 
distal portions of the nerves. Prevention and food control are very 
important, especially those related to the mechanisms that involve 
carbohydrate metabolism and its peripheral resistance. The original 
results commented here are relevant for the continuous study of 
this serious but old illness, but quite current in the medical and 
therapeutic clinic.
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Introduction
Nearly 387 million people have diabetes worldwide, 
and this epidemic disease continues to rise at an 
alarming rate, being expected 552 million by 2030. 
[1, 2, 11, 14] Type 2 diabetes mellitus (T2DM) ac-
counts for 95% of diagnosed diabetes, [2, 3] and its 
complications, including heart disease and stroke, 
result in significant morbidity and mortality, repre-
senting the first and fourth most common causes 
of death, respectively, in the U.S. [2, 3]
Diabetes mellitus (DM) is the most common me-
tabolic disease with a high prevalence rate in hu-
man society that eventually leads to the peripheral 
nervous system complications in a great number of 
patients. It is a chronic metabolic disorder that leads 
to long-term complications affecting some sites 
such as heart, kidney, retina, vessels and periphe-
ral nerves. [4, 5, 10] Peripheral neuropathy is one 
of the common complications of diabetes which in 
turn increases the risk of other diabetes complica-
tions such as foot ulcers and amputation. [6, 7, 10] 
Almost more than half of diabetic patients suffer 
from different forms of neuropathy after passing 
1-2 decades of their diseases. [8, 10] Abnormalities 
of polyol pathway and defects of protein kinase C 
metabolism which cause nerve demyelination have 
also been described in diabetic peripheral neuro-
pathy. [9, 10] Based on these mechanisms of injury, 
various prevention and treatment strategies have 
been already suggested and are under investiga-
tion. [10]
As mentioned before, peripheral neuropathies are 
a major cause of morbidity in patients with diabetes 
mellitus, affecting as many as 50% of patients with 
diabetes. [12, 14] They can cause acute and chronic 
neuropathic pain, hyperalgesia and impaired nerve 
conduction velocities, which can cause significant 
morbidity of these patients and affect their daily 
activities. [13, 14]
There are two main types of DM. Type 1 DM 
(T1DM) results from the body’s failure to produce 
insulin and type 2 DM (T2DM) results from insulin 
resistance, where cells fail to use insulin properly, 
sometimes combined with an absolute insulin de-
ficiency. An increase in blood glucose levels repre-
sents a recognized diagnostic criterion for diabe-
tes. [15] The best predictor of T2DM macrovas-
cular complications is the preceding presence of 
microvascular complications, particularly diabetic 
polyneuropathy (DPN) and diabetic nephropathy 
(DN). [2]
DPN consists of demyelization and axonal de-
generation of peripheral nerves, [16], leading to 
slowing of nerve conduction velocity and reduction 
of the amplitude of the compound muscle and sen-
sory nerve action potentials. [16, 23] These features 
of diabetic polyneuropathy are observed in human 
diabetes [16, 24] and in experimentally induced dia-
betic animals. [17-23]
DPN is one of the main complications of diabetes, 
which may impair the peripheral nerve regenera-
tion. Though the causes for failed regeneration in 
diabetic peripheral nerves are not completely eluci-
dated, possible etiopathologies have been reported, 
such as structural changes in peripheral blood ves-
sels and reductions in blood flow, [25, 54] delays 
in recruitment of macrophages to clean degrading 
myelin in injured peripheral nerve fibers, [26, 54] 
and reductions in neurotrophic supports for nerve 
tissue regeneration. [27, 54]
DPN is not a single entity, but encompasses se-
veral neuropathic syndromes, including sensory and 
motor defects. A wide variety of sensorimotor symp-
toms which affects approximately 50% of diabetic 
patients is presented by patients with DPN. Changes 
in the neural circuits may occur in the early stages 
in diabetes and are implicated in the development 
of DPN. [28]
Early physiological disorders such as nerve con-
duction slowing and sensory loss can be used to 
diagnose and stage diabetic neuropathy, [29, 34] 
and may predict the onset of degenerative changes 
in neurons, Schwann cells and blood vessels. Nerve 
biopsy studies have described segmental demye-
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lination and axonal degeneration of large fibers 
as common features of nerve pathology, [30, 34] 
while the use of skin biopsies and corneal confocal 
microscopy has emphasized the early damage of 
small sensory fibers terminals. [31, 34] The two do-
minant risk factors for diabetic neuropathy are poor 
glycemic control and duration of diabetes which are 
widely appreciated [32, 34] Other risk factors for 
neuropathy that emerge after correcting the hy-
perglycemia include increased plasma triglyceride 
levels, body-mass index, smoking and hypertension. 
[33, 34]
Methods
Despite considerable researches on DPN, evidence 
for pathophysiological changes in the nervous sys-
tems underlying the impairment of motor function 
still lacks neurostructural evidence. Previous stu-
dies have focused on the role of peripheral nerves 
in DPN. Increasing evidence now indicates that the 
onset of DPN might be in all levels of the nervous 
system, including both the Peripheral Nervous Sys-
tem (PNS) and the Central Nervous System (CNS). 
[28, 35, 36, 39] Although the involvement of both 
PNS and CNS in DPN has previously been recog-
nized, the underlying mechanisms remain poorly 
understood, particularly in the changes of the 
neural circuits between spinal nerves and spinal 
cord via the Dorsal Root Ganglia (DRG) and ven-
tral root. Thus, investigating the alterations in the 
neural circuits is essential for understanding the 
development of the sensory and motor defects 
in DPN. It is important remember that the spinal 
nerves conduct mixed signals, including sensory 
and motor information from nerve endings in the 
PNS, [28, 37] And finally, that the various types of 
DRG neurons send their central axonal processes 
to different parts of the spinal dorsal horn in the 
CNS. [28, 37, 38]
Several morphometric studies have demonstrated 
abnormalities of the myelinated and unmyelinated 
fibers in painful DPN. [15, 39, 40, 41, 42]. Equally, a 
significant loss in dermal fiber density was observed 
in preclinical models of diabetes.[15] Besides, the 
mechanical response properties of spinal neurons 
have been shown to be altered in different models 
of neuropathic pain, including DPN. [15, 43, 44]
Results have shown that the neuronal basis of dia-
betes-induced neuropathic pain might differ across 
models. This demonstrates the complexity of the 
neuronal reorganization following hyperglycemia-
induced neuronal damage and the resulting cha-
llenge for an effective treatment of diabetes-based 
neuropathic pain. [15]
Different models for diabetic neuropathy in the 
rat have demonstrated distinct response properties 
of spinal wide dynamic range (WDR) neurons. This 
specificity in electrophysiological properties of WDR 
neurons for every investigated model might reflect 
differences in the pathological mechanisms in pain 
transmission and also suggest substantial differen-
ces underlying diabetes-induced neuropathic pain in 
T1DM and T2DM, as well as between chemically-
induced and genetically determined diabetic rats. 
These differences are most likely due to a variety in 
metabolic changes, pathology, disease progression 
as well as severity and duration of diabetes. It can 
be assumed that, depending on the severity and du-
ration of diabetes, it is the degree of spinal reorga-
nization, due to the degeneration of small afferents, 
for example, which leads to the deafferentation of 
spinal neurons and the abnormal branching of A-b 
fibers. [16, 45, 47] 
Moreover, the anatomical framework of the spi-
nal cord allows the transfer of specific inputs to 
localized subsets of dorsal horn neurons. This allows 
the separation in signal transduction pathways for 
low-intensity stimuli and noxious stimuli. The struc-
tural reorganization on the level of the spinal cord 
might contribute to the development of the pain. 
[15, 45, 46]
The different mechanisms involved in different 
pain sensations are still poorly understood. Especially 
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in a complex and diverse disease as DPN, the plastic 
reorganization processes of the somatosensory sys-
tem along the pain pathway need further detailed 
investigation. It was detected complex alterations in 
spinal neuronal response properties of hyperglyce-
mic rats, which varied significantly depending on 
stimulus force and quality. The electrophysiological 
technique allows a very detailed qualitative charac-
terization of neuronal hyperexcitability, in specific 
diabetes models that complement the behavioral 
findings. These data reveal that specific neuronal 
properties can be associated with behavioral sen-
sory abnormalities measured by evoked response 
studies in conscious rats. [15]
Pharmacological treatments have been used to 
accelerate regeneration of peripheral diabetic ner-
ves, such as angiotension II type 1 receptor blockers, 
[47, 54] neurotrophic factors and anti-apoptotics. 
[48, 54] Recent studies have also shown that herbal 
medicine may be an alternative treatment for neu-
ronal repair and regeneration in diabetic peripheral 
neuropathy. [49, 54] As for nonpharmacological ap-
proaches, a number of studies have reported the 
efficacy of various electrotherapies on regenerating 
diabetic nerves, such as electro-magnetic fields, [50, 
54] transcutaneous electrical stimulation [51, 54] 
and percutaneous electrical stimulation. [52, 54] Of 
all these electrotherapies, the percutaneous elec-
trical stimulation not only can be precisely placed 
on muscles or nerves, but it is also safe with rare 
complications. [53, 54]
Results
The emerging clinical recognition of multiple risk 
factors associated with diabetic neuropathy has 
not been widely explored in animal models, where 
a reductionist approach has largely been adopted 
and a glucocentric view of pathogenic mechanisms 
has historically dominated [34, 55]. This approach 
is consistent with the primary risk factors for hu-
man diabetic neuropathy and the widely studied 
streptozotocin (STZ) model of type 1 diabetes repli-
cates a number of features of diabetic neuropathy 
such as large fiber conduction slowing, sensory 
dysfunction and depletion of unmyelinated epi-
dermal nerve fibers in the skin [34, 56, 57] STZ-
diabetic rodents are less successful at modeling the 
degenerative pathology of myelinated fibers. The 
most widely and consistently reported structural 
disorder in nerve trunks of STZ-diabetic rats is re-
duced axonal caliber of myelinated fibers [20, 35, 
58, 59] while degenerative pathology occurs in the 
most distal nerves of STZ-diabetic mice only after 
many months of hyperglycemia. [34, 60]
The absence of more dramatic nerve pathology 
is frequently attributed to the relatively short dura-
tions of hyperglycemia attainable in rodent models 
of diabetes. Direct investigation of the pathogene-
sis of segmental demyelination has been particu-
larly impeded by the absence of Schwann cell and 
myelin pathology in the common models of diabe-
tic neuropathy, and a considerable leap of faith is 
necessary when attempting to translate therapeu-
tics from preclinical models to clinical trials. [34]
Simalary to Gregory JA et al [34], we conducted a 
small experiment in order to show the degenerative 
pathology in distal nerves of STZ-diabetic induced 
[4] rats caused by the hyperglycemia. We used 12 
male Wistar rats (n=12) at 42 days of age. They 
were induced to become diabetic with streptozo-
tocin (STZ) [4]. Half of these animals (n=6) were 
fasted for 12 hours prior to being injected intra-
peritoneally with STZ (60 mg/kg) in a single dose. 
Control animals (n=6) received vehicle. Ten weeks 
after STZ injection the animals were perfused in-
tracardially with Karnovsky solution. Right and left 
sciatic nerves were dissected and processed for 
epoxy resin embedding. Samples were imaged with 
a transmission electron microscope. Compare the 
control group nerves (Figure 1) with nerves of STZ-
diabetic induced rats (Figure 2). These results were 
presented at the Expeirmental Biology Congress in 
Boston, USA, 2013.
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Although diabetic neuropathy more commonly 
affects the peripheral nerves [35, 61], or the optic 
nerve, and the autonomic fibers, hyperglycemia can 
also cause damage to other cranial nerves, such as 
the vestibulocochlear, shown by us in Figure 3.
Schwann cell metabolism is certainly compromi-
sed by diabetes, [34, 61, 70] as indicated by de-
pletion of nerve ciliary neurotrophic factor (CNTF) 
levels, [34, 62, 63] but myelin thickness, structure 
and ultrastructure are preserved when viewed in 
appropriately fixed tissue. Speculation as to why 
demyelination does not develop in diabetic rodents 
has frequently evoked the short absolute duration 
of exposure to diabetes in rats when compared to 
humans. [3]
Diabetic rats develop slowing conduction on lar-
ge fiber within weeks of onset of hyperglycemia 
that is initially reversible and has a metabolic patho-
genesis. [35, 65, 66] A reduction in axonal caliber 
can be detected after 2-3 months of diabetes and 
contributes to progressive conduction slowing [34, 
Figure 1 A-D:  Electron micrographs of transver-
se sections of the sciatic nerve 
of control Wistar rat, presenting 
a well organized endoneurium. 
Note the presence of large and 
small myelinated fibers, with uni-
form myelin sheath enveloping the 
axon. Clustering of unmyelinated 
axons surrounded by Schwann 
cells profiles are also present. The 
Schwann cell nucleus are noticea-
ble through its close relationship 
to the myelinated or unmyelinated 
axons. Note the presence of seve-
ral mitochondria in the axoplasm.
Magnification: A, B, C = x10,000 and D = x6,700.
Figure 3:  Electron micrographs of transverse sec-
tions of the vestibulocochlear nerve in 
STZ-diabetic induced rats. Note the pre-
sence of myelin folds and axonal atro-
phy, marked by asterisks.
A) x5,000 and in smaller size the image shows the same results x2,700 (B).
Figure 2 A-F:  Representative electron-microgra-
phs of the sciatic nerve of chronic 
STZ-induced diabetic rats.
A-B) Asterisks show axonal atrophy of large myelinated fibers and arrows 
show fibroblast profiles in A and fibroblast nucleus in B. x4,000. C) Sugges-
tive image of a macrophage in the endoneurium, involving an unmyelinated 
fibers with their pseudopods. x4,000. In large magnification, the insertion 
in the center shows a pseudopod involving an unmyelinated fiber and a 
giant mitochondria shown by the white arrow. x27,000. D) Note the thin 
myelinated fibers showing signs of demyelination. x5,000. E) Another thin 
fiber demyelination image x5,000. F) Note in high magnification, a thin 
fiber demyelination (arrowhead) and the presence of a vacuole in the myelin 
sheath. x20,000.
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58, 59, 66] However, rodent models of diabetic 
neuropathy are frequently faulted as showing little 
reliable evidence of overt structural damage to mye-
linated fibers such as the segmental demyelination, 
remyelination and Wallerian degeneration that cha-
racterizes human diabetic neuropathy. [34, 67] The 
resilience of myelin in diabetic rodents is surprising 
given the metabolic stress placed on Schwann cells 
by hyperglycemia-driven flux through aldose reduc-
tase. [34, 68, 69]
Acute nerve conduction velocities (NCV) slowing 
reported in other STZ-diabetic rat strains has been 
attributed to nerve ischemic hypoxia. [35, 71] It is 
notable that reductions in nerve blood flow (23 %) 
and conductance (20 %) after 6 months of STZ-
induced diabetes in WKY rats were substantially less 
than the 50 % decrease widely reported to occur 
following 2–4 weeks of diabetes in other strains 
using a variety of techniques. [34, 71-73] Reduced 
nerve blood flow after 6 months of diabetes in 
WKY rats was associated with a 29 % reduction in 
endoneurial blood vessel number. A slowly develo-
ping vasculopathy may contribute to reduced nerve 
blood flow in this strain. In general, STZ-diabetic 
WKY rats lacked the dramatic early nerve conduc-
tion slowing reported in other strains and displayed 
a slowly evolving impairment of conduction accom-
panied by loss of endoneurial blood vessels and re-
duced axonal radial growth. [34]
SHR rats are hyperactive, [36, 74] and findings 
of reduced body weight and plasma insulin levels 
compared to WKY rats were consistent with prior 
reports. [34, 75, 76] SHR rats also showed progressi-
vely developing NCV deficits and attenuated axonal 
radial growth in the sciatic and sural nerves, without 
myelinated fiber loss or any change in fiber densi-
ty. These features have been previously reported, 
[34, 77] along with generalized myelin thinning in 
formalin-fixed paraffin embedded sections. [34]
Axons with disproportionately thin myelin 
sheaths were observed, while not sufficiently fre-
quent to impact the average myelin thickness of 
all fibers in the nerve cross section, and they were 
more frequent in nerves from SHR rats than in 
age-matched WKY rats. Identification of super-
numerary Schwann cell processes encircling thinly 
myelinated fibers reflects demyelination and sub-
sequent remyelination. [34, 78, 79] Similar profiles 
are seen in nerve from diabetic patients [34, 67, 
68] and can cause conduction slowing indepen-
dent of axonopathy. [34, 80] Although the propor-
tion of thinly myelinated fibers was low, each cross 
section analyzed illustrates one of approximately 
50 Schwann cells that myelinate an axon along 
its length, assuming a nerve of 5 cm length and 
an intermodal distance of 1 mm. [34, 81] Myelin 
disorders are equally infrequent in cross sections 
of nerves from patients with neuropathy. [34, 80] 
It is not clear yet if myelin thinning persists along 
the entire length of occasional axons or if it is in-
termittently segmental along the length of many 
fibers. If the latter occurs, up to 10 % of all fibers 
within the sciatic nerve could be affected at some 
position (0.2 % in one crosssection x 50 potential 
internodes). Teased fiber studies may resolve this 
issue. Early NCV slowing in SHR rats may reflect 
segmental demyelination and partial remyelina-
tion, whereas the later period of attenuated NCV 
increase also includes a contribution from restric-
ted axonal maturation. The findings support the 
suggestion that hypertension can promote peri-
pheral neuropathy and serve as an independent 
risk factor for neuropathy in diabetic patients. [34, 
82-86]
Current murine data suggest that both elevated 
cholesterol and obesity may be particularly instru-
mental in inciting nervous system damage. Some 
authors contend that dyslipidemia and visceral adi-
posity in males form a network with insulin resistan-
ce, hypertension, and hyperglycemia to injure the 
peripheral nervous system, particularly myelinated 
large fibers. These murine data support that this 
network of metabolic impairments activates detri-
mental feed-forward cycles of local and systemic 
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oxidative stress and dysregulated energy homeos-
tasis with local mitochondrial dysfunction and in-
flammation, thus resulting in neural injury and DPN. 
Corroborating this idea, there are some clinical stu-
dies showing that dyslipidemiais strongly correlated 
with DPN [2, 87] and that lowering cholesterol, not 
glycemia, is significantly associated with decreasing 
lower-extremity amputations among patients with 
diabetes [2, 88].
In summary, the glycemic control alone is not 
sufficient to ameliorate injury to large myelinated 
fibers in murine models of T2DM and DPN, likely 
because of the persistence of hypercholesterolemia 
as well as local neural dysfunctional lipoprotein sig-
naling. These findings along with similar results in 
several large clinical trials in patients with T2DM 
and DPN collectively suggest that treatment of the 
metabolic syndrome as a whole and not just hy-
perglycemia is required to effectively target DPN in 
T2DM. [2]
Conclusion
Impaired myelinated axon population of peripheral 
nerves as a consequence of regenerative failure has 
been clearly seen in the rat model of diabetes. [54, 
89, 90] It could be caused by slow infiltration of en-
doneurial macrophages, delaying Wallerian degene-
ration and subsequent nerve regeneration. Another 
possibility that the regenerative deficit is related to 
decreased action of vasoactive neuropeptides such 
as calcitonin gene-related peptide (CGRP) in diabe-
tics which may render an ischaemic environment in 
nerve microvessels following nerve injury. [26, 54]
Percutaneous electrical stimulation (ES) of 1mA 
or above was suggested as possible inductor of a 
transient rise in skin perfusion in diabetic rats, res-
toring the blood circulation that is essential for sti-
mulation of these regenerative processes. As seen 
in the medical literature, it was found that diabetes 
has caused a slowdown in NCV and latency in rats, 
which are similar to the early neuropathic changes 
in diabetic patients. [54, 98, 99] The data demons-
trated that ES treatment, especially at 10 mA, could 
produce profound improvements in NCV and laten-
cy in the diabetic rats. [54]
Count and density of myelinated axons in the 
mid-portion of regenerated sciatic nerves showed 
to be dramatically decreased in the diabetic groups 
compared to those in the non diabetic normal ani-
mals. The vestibulocochlear nerve, a special afferent 
nerve is also directly affected, perhaps because of 
its rich vascularization and immense fiber density. 
Several authors have reported similar results that 
rats with diabetes usually have a decreased rate 
of nerve regeneration. [47, 54, 93] However, the 
reduced regeneration rate after axotomy in diabe-
tes was elevated in the rats as they received ES 
treatment at 10mA or or above. This improvement 
is thought to be due to these aforementioned ES’s 
positive effects, i.e., accelerated circulatory blood 
flow, increased expression of CGRP, or improved 
macrophage infiltration in the diabetic nerves. [54] 
We must continue with more studies to try to elu-
cidate several questions still in studies, the experi-
mental model of diabetes only represents the effect 
of type I diabetes, type 2 diabetes related to fee-
ding and metabolism of carbohydrate is still more 
compelling still and does not have an experimental 
model yet .
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